The role of protein phosphorylation in the Pasteur effect -the phenomenon whereby anaerobic conditions stimulate glycolysis -has not been addressed. The AMP-activated protein kinase (AMPK) is activated when the oxygen supply is restricted. AMPK acts as an energy-state sensor and inhibits key biosynthetic pathways, thus conserving ATP. Here, we studied whether AMPK is involved in the Pasteur effect in the heart by phosphorylating and activating 6-phosphofructo-2-kinase (PFK-2), the enzyme responsible for the synthesis of fructose 2,6-bisphosphate, a potent stimulator of glycolysis.
Background
To maintain its function, the heart requires a constant supply of fuels and oxygen. When the oxygen supply is not limited (normoxic conditions), these fuels are completely oxidised in the mitochondria (reviewed in [1] ). Myocardial ischaemia induces a shift to anaerobic metabolism, with a rapid stimulation of glycolysis [2, 3] . This anaerobic stimulation of glycolysis, called the Pasteur effect, can occur in different mammalian tissues. The role of protein phosphorylation in this phenomenon has not been addressed. In the heart, a protein kinase that is activated by ischaemia could be responsible for the stimulation of glycolysis in this condition.
The AMP-activated protein kinase (AMPK) is a protein kinase that is activated in anaerobic conditions. AMPK is a heterotrimeric protein composed of a catalytic subunit (α) and two regulatory subunits (β and γ) [4, 5] . Isoforms of all three subunits have been identified [6, 7] , but the physiological significance of the isoforms is unclear. In the heart, the catalytic α2 isoform is more abundant than α1 [6] . AMPK is activated by an increase in the intracellular AMP:ATP ratio and so acts as a sensor of the energy state ('fuel gauge') of the cell (for a review, see [8] ). The AMP:ATP ratio is known to increase when the oxygen supply is restricted or in the presence of inhibitors of mitochondrial oxidative phosphorylation. In various tissues (liver, adipose tissue and skeletal muscle), AMPK phosphorylates and inactivates several key enzymes in energy-consuming biosynthetic pathways, thereby conserving ATP. This is the case for acetyl-CoA carboxylase (ACC), 3-hydroxy-3-methylglutarylCoA reductase [9] , glycogen synthase [10] and creatine kinase [11] , which control the synthesis of fatty acids, cholesterol, glycogen and phosphocreatine, respectively. In skeletal and cardiac muscle, AMPK is thought to mediate the recruitment of glucose transporters (GLUT4) by an unknown mechanism that is distinct from that of insulin [12, 13] . Our hypothesis is that myocardial hypoxia stimulates glycolysis in a concerted manner, which involves GLUT4 recruitment and 6-phosphofructo-2-kinase (PFK-2) activation, and is mediated by AMPK.
PFK-2 is a bifuntional enzyme, termed PFK-2/fructose-2,6-bisphosphatase (FBPase-2), which controls the synthesis and degradation of fructose 2,6-bisphosphate, respectively. Fructose 2,6-bisphosphate is a potent stimulator of 6-phosphofructo-1-kinase (PFK-1), a key enzyme of glycolysis and, as such, it is considered as a ubiquitous glycolytic signal (for a review, see [14] ). Distinct isozymes of PFK-2 exist in mammalian tissues. They are encoded by different genes and differ in molecular mass, kinetic and immunological properties, and phosphorylation by protein kinases (for reviews, see [14, 15] ). The heart (H) isozyme contains a carboxy-terminal regulatory domain that is absent in the liver (L) isozyme and can be phosphorylated on both Ser466 and Ser483 in vitro by protein kinase B (PKB), cyclic AMP-dependent protein kinase (PKA), p70 ribosomal S6 kinase (p70 S6k ) and mitogen-activated protein kinase-activated protein kinase-1 (MAPKAPK-1) [16] . Phosphorylation activates PFK-2 with no effect on FBPase-2 activity. Phosphorylation of Ser466 is sufficient to increase the V max , whereas phosphorylation of both Ser466 and Ser483 is required to decrease the K m for fructose 6-phosphate of PFK-2 [17] . In accordance with its capacity to be phosphorylated by several protein kinases, PFK-2 is activated in hearts stimulated by adrenaline or insulin, or submitted to high workload, and correlates with the stimulation of glycolysis observed under these conditions [1] .
Here, we studied whether heart PFK-2 could be a substrate of AMPK and we investigated the effect of anaerobic conditions on AMPK and PFK-2 activity in perfused rat hearts. We also transfected human embryonic kidney (HEK)-293 cells with cDNA constructs encoding recombinant wild-type bovine heart PFK-2 and both wild-type and dominant-negative forms of AMPK, in order to assess the role of AMPK in the activation of heart PFK-2 in anaerobic conditions.
Results
Phosphorylation and activation of heart PFK-2 in vitro by AMPK Recombinant bovine heart PFK-2 carrying a carboxy-terminal hexa-histidine tag (His 6 -PFK-2) was phosphorylated by rabbit liver AMPK with a stoichiometry close to 1 mole phosphate incorporated per mole enzyme subunit. The rate of phosphorylation was stimulated by 0.2 mM AMP ( Figure 1a ) and correlated with PFK-2 activation (Figure 1b) . Similarly, protein phosphatase 2A (PP2A)-mediated dephosphorylation of PFK-2 that had been previously phosphorylated by AMPK correlated with PFK-2 inactivation (Figure 1c) . Such a correlation between activation and phosphorylation has already been described for heart PFK-2 phosphorylated by PKB, p70 S6k and MAPKAPK-1 [16] . PFK-2 activation by AMPK resulted from a 2.5-fold increase in V max (49 ± 5 to 123 ± 10 mU/mg protein; n = 3), with little (less than 20%) or no change in K m for fructose 6-phosphate and MgATP or in IC 50 for magnesium citrate (see Supplementary material). In contrast, phosphorylation of His 6 -PFK-2 by PKB increased the V max (twofold) but also decreased the K m for fructose 6-phosphate (twofold) and decreased the sensitivity towards magnesium citrate inhibition (twofold). Phosphorylation of His 6 -PFK-2 did not affect FBPase-2 activity (see Supplementary material).
To identify the site(s) phosphorylated by AMPK, His 6 -PFK-2 was maximally phosphorylated with Mg[γ-32 P]ATP and AMPK. After purification by SDS-PAGE and digestion with trypsin, peptides were separated by reversedphase high-pressure liquid chromatography (HPLC). A single radioactive peak was detected ( Figure 2a ) and its radioactivity was decreased (twofold) when phosphorylation was performed without AMP (data not shown). The elution time of this peak was the same (Figure 2a,b) as that of the first peak obtained after phosphorylation of His 6 -PFK-2 by PKB and which contained phosphorylated Ser466 [17] . The residue phosphorylated by AMPK was identified by analysing the labelled peak by matrixassisted laser desorption-ionisation mass spectrometry (MALDI-MS), nanoelectro-spray ionisation tandem mass spectrometry (nanoESI-MS/MS) and by solid-phase sequencing ( Figure 2c ). The labelled peptide contained the sequence 464 RNSFTPLSSSNTIR 477 in which the burst of radioactivity occurred at Ser466 (Figure 2c ). In agreement with the identification of Ser466 as the phosphorylated residue, a constitutively active S466E mutant of His 6 -PFK-2 was not phosphorylated and could not be further activated by AMPK (data not shown). This mutant could, however, be phosphorylated by PKB on Ser483 [17] . The recognition motif for phosphorylation by AMPK, as deduced from sequences surrounding its known phosphorylated sites, contains hydrophobic residues at P-5 and P+4 (where P is the phosphorylated site) and a single basic residue at P-3 or P-4 [8] . This motif differs slightly from that in endothelial nitric oxide synthase (eNOS), which contains hydrophobic residues at P-4 and P+3 [18] . The phosphorylation site in heart PFK-2 (VRMRRNS SFTPLS; the phosphorylated Ser is bold and italicized) shares similarities with both motifs. It contains hydrophobic residues at P-4 and P+4 and a basic residue at P-3.
In the experiments described above, we used AMPK purified from rabbit liver, which contains both α1βγ and α2βγ complexes, similar to the enzyme purified from rat liver [19] . To study the relative specificity of the individual isoforms, we isolated α1βγ-and α2βγ-specific complexes by immunoprecipitation from rat liver and compared their activity using either His 6 -PFK-2 or ACC as a substrate. Both isoforms phosphorylated His 6 -PFK-2 at the same rate, which was about half the rate of phosphorylation of ACC (data not shown). We also compared the kinetic properties towards SAMS, a known synthetic substrate derived from ACC [20] , and the peptide MR6 (containing Ser466 of cardiac PFK-2). The V max and K m values for SAMS were the same for both isoforms. For the MR6 peptide, the V max and K m of α2βγ were twice that of α1βγ. The latter differences compensated for each other, such that the value of k cat /K m (sometimes called 'catalytic efficiency') was the same. Nevertheless, this value was 3-4 times lower than for SAMS, confirming that ACC is a better substrate of AMPK than His 6 -PFK-2 (see Supplementary material). We also studied the kinetic properties of the AMPK isoforms towards a peptide containing a serine residue in a sequence homologous to that surrounding Ser466 in heart PFK-2. This sequence is found in a PFK-2 isozyme present in some tumour cells [21] and placenta [22] . This peptide (MR47) was equally phosphorylated by both AMPK isoforms, although the efficiency was about 10 times less than that observed with the MR6 peptide (see Supplementary material).
Activation of AMPK and PFK-2 in perfused rat hearts
Perfused rat hearts were submitted to different periods of no-flow ischaemia to study whether AMPK activation would correlate with PFK-2 activation and with an increase in fructose 2,6-bisphosphate concentration. AMPK, which was almost completely inactive under aerobic conditions, was activated 10-fold after 10 minutes of ischaemia (both AMPK isoforms were activated) and its activity returned towards basal levels after 30 minutes of ischaemia ( Figure 3a ). Ischaemia activated PFK-2 and increased fructose 2,6-bisphosphate concentration, both processes following AMPK activation with a slight delay ( 
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HPLC profile and solid-phase sequencing of 32 P-labelled tryptic peptides of His 6 -PFK-2 phosphorylated in vitro by AMPK and PKB. the stimulation of heart glycolysis by ischaemia, which was also transient and disappeared during prolonged and severe ischaemia [23] . The transient nature of the phenomenon probably explains our previous failure to observe an increase in fructose 2,6-bisphosphate concentration in hearts submitted to ischaemia/anoxia for 30 minutes [24] .
Perfusion for 10 minutes with 5 µM oligomycin or 3 µM antimycin, or under anoxic or ischaemic conditions activated both AMPK (at least 10-fold) and PFK-2 (2-3-fold) and doubled the concentration of fructose 2,6-bisphosphate (Table 1) . Maximal effects were already obtained with 0.5-1 µM of both inhibitors (data not shown). The extent of activation of AMPK correlated with the increase in the AMP:ATP ratio (see Supplementary material). In contrast, perfusion with 5-aminoimidazole-4-carboxamide (AICA) riboside had no effect on AMPK and PFK-2 activity, and on fructose 2,6-bisphosphate concentration. AICA riboside is known to activate AMPK in liver after its phosphorylation into AICA ribotide (also called ZMP), an analogue of AMP responsible for AMPK activation [25, 26] . However, in hearts perfused with AICA riboside, the concentration of ZMP, ZDP and ZTP were barely detectable (data not shown), in agreement with previous work performed on rabbit cardiomyocytes [27] . The lack of effect of AICA riboside on AMPK activity in heart differs from the results reported for isolated papillary heart muscle cells [13] . Whatever the reason for this discrepancy, we did not detect any significant accumulation of ZMP, consistent with the lack of AMPK activation.
The kinetic properties of PFK-2 from normoxic or ischaemic hearts were compared. The V max of PFK-2 from ischaemic hearts was twice that of normoxic hearts. No significant changes in K m for MgATP and fructose 6-phosphate, or in IC 50 for magnesium citrate could be detected. Therefore, ischaemia induces changes in kinetic properties of PFK-2 in vivo that are similar to those observed after phosphorylation of His 6 -PFK-2 by AMPK in vitro (see Supplementary material).
Activation of AMPK and PFK-2 in cell lines
We first compared the effect of 1 mM AICA riboside or 0.5 µM oligomycin on endogenous AMPK activity in four different cell lines (CHO, FTO-2B, HEK-293 and COS-7). AMPK activation by oligomycin was observed in all cell lines, whereas AICA riboside activated AMPK (more than twofold) only in FTO-2B and CHO cells (see Supplementary material and Figure 4a ). The failure to detect an activation of AMPK following incubation with AICA riboside appears to be due to a lack of accumulation of ZMP within the cells (D.C., unpublished results), as in the perfused hearts.
The effects of AICA riboside or oligomycin on transfected His 6 -PFK-2 activity were then studied in FTO-2B and HEK-293 cells. In such experiments, the treatment lasted for only 10 minutes and was therefore too short to affect the enzyme content, as verified by immunoblots. Endogenous PFK-2 activity was unaffected by AICA riboside or oligomycin treatment (data not shown). Transfection of His 6 -PFK-2 in FTO-2B cells resulted in a sevenfold overexpression (endogenous, 13 ± 3 µU/mg protein; transfected with 10 µg DNA, 97 ± 5 µU/mg protein; n = 3). Incubation for 10 minutes with 1 mM AICA riboside or 0.5 µM oligomycin increased transfected PFK-2 activity (Figure 4b ). In HEK-293 cells, the activity of transfected His 6 -PFK-2 was about 60 times that of endogenous PFK-2 (endogenous, 12 ± 1 µU/mg protein; transfected with 10 µg DNA, 706 ± 13 µU/mg protein; n = 3). In these cells, 0.5 µM oligomycin activated transfected PFK-2 after 10 minutes of incubation (Figure 4b ). This activation was not due to other protein kinases such as PKB, MAPKAPK-1 and p70 S6k because it was not antagonised by PD 98059 (50 µM), rapamycin (100 nM) or wortmannin (100 nM), which prevent the activation of these kinases (Figure 4 ).
To determine the in vivo phosphorylation site(s) involved in the oligomycin-induced activation of PFK-2, HEK-293 cells were transfected with His 6 -PFK-2. After labelling with 32 P, the transfected cells were incubated for 10 minutes with or without 0.5 µM oligomycin. Immunoprecipitation and SDS-PAGE of transfected His 6 -PFK-2 followed by autoradiography revealed a single 32 P-labelled band with the expected M r of 61,000 (Figure 5a ). Its labelling was increased about twofold in oligomycin-treated cells. The labelled band was digested with trypsin and peptides were separated by reverse-phase HPLC (Figure 5b ). The elution profile from unstimulated cells displayed two major peaks (peaks 1 and 2) followed by two minor peaks (peaks 3 and 4). This profile was similar to that previously described [17] . The first two peaks correspond to peptides containing phosphorylated Ser522 and Ser528, which may represent MAP kinase(s) sites and which do not change PFK-2 activity [17] . Oligomycin increased the labelling of peak 3 ( Figure 5c ). The elution time of this peak corresponds to that of the peptide containing phosphorylated Ser466 in vitro (compare Figures 2b and 5c ). The S466E His 6 -PFK-2 mutant (10 µg DNA) was also transfected in HEK-293 cells. Oligomycin did not activate the S466E His 6 -PFK-2 (control, 665 ± 15 µU/mg protein; oligomycin, 656 ± 23 µU/mg protein; n = 3). The elution profile of radioactive peaks obtained with this mutant indicated that
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To assess the role of AMPK in the activation of PFK-2 by oligomycin, the effect of co-expression of PFK-2 with a catalytically inactive mutant of α1 AMPK (α1DN AMPK) was studied in HEK-293 cells. Expression of α1DN AMPK in primary rat hepatocytes acted as a dominantnegative inhibitor of endogenous AMPK by competing for the binding of the β and γ subunits [28] . We verified that transfection with α1DN AMPK abolished the oligomycininduced activation of both endogenous and cotransfected wild-type (α1βγ and α2βγ) AMPK in HEK-293 cells (Figure 6a ).
Having confirmed the dominant-negative character of α1DN AMPK, we tested whether α1DN AMPK could interfere with the effect of oligomycin on His 6 -PFK-2 activation. In the absence of α1DN AMPK, there was a time-dependent and concomitant activation of both AMPK and transfected His 6 -PFK-2 by oligomycin (Figure 6b,c) . Furthermore, immunoblotting with antibody raised against phosphorylated Ser466 revealed a similar timedependent phosphorylation of His 6 -PFK-2 on Ser466 (Figure 6d ). In contrast, when α1DN AMPK was coexpressed, phosphorylation and activation of transfected His 6 -PFK-2 by oligomycin was almost completely abolished (Figure 6b-d) .
Taken together, these results provide strong evidence that the oligomycin-induced activation of heart PFK-2 is due to phosphorylation by AMPK. The data support our hypothesis that AMPK mediates PFK-2 activation under conditions leading to ATP depletion in the heart.
Discussion
AMPK activates heart PFK-2 by phosphorylating Ser466.
Our in vitro and in vivo studies fulfil the criteria put forward by E.G. Krebs [29] to demonstrate that phosphorylation of a target protein has physiological relevance. The experimental evidence can be summarised as follows: first, PFK-2 is phosphorylated in vitro by AMPK to a significant extent; second, AMPK-phosphorylated PFK-2 can be dephosphorylated by PP2A; third, phosphorylation correlates with PFK-2 activation; fourth, AMPK activation in heart or cells in culture correlates with PFK-2 activation; fifth, the same site, Ser466, is phosphorylated by AMPK in vitro and in intact cells; and, finally, PFK-2 activation by oligomycin in transfected cells is abolished by a dominantnegative mutant of AMPK. Heart PFK-2 therefore represents a new substrate of AMPK and is activated by AMPK in anaerobic conditions. It is noteworthy that PFK-2 is only the second substrate for AMPK known to be activated following phosphorylation, the first being eNOS [18] .
AMPK is known to inactivate key enzymes in biosynthetic pathways, thereby conserving energy. Until recently, however, AMPK was not known to stimulate ATP production. Our results indicate that this could occur under anaerobic conditions in the heart. The AMPK-mediated activation of PFK-2 stimulates the flux through PFK-1 by increasing fructose 2,6-bisphosphate concentration. This would be expected to lead to a stimulation of ATP production through glycolysis. To our knowledge, this is the first demonstration of protein phosphorylation being involved in the Pasteur effect. This phenomenon is superimposed on the well-known and direct stimulation of PFK-1 by changes in adenine nucleotide concentrations (particularly a fall in ATP and a rise in AMP). Therefore, the increase in AMP:ATP ratio stimulates PFK-1 through two mechanisms: a direct allosteric stimulation of PFK-1 and an indirect mechanism involving the phosphorylation of PFK-2 by AMPK.
Activation of PFK-1 and PFK-2 is unable to stimulate glycolysis by itself [1] . Overall flux can only increase if the supply of glucose 6-phosphate is also increased. Therefore, besides PFK-1/PFK-2 activation, the stimulation of glucose transport by AMPK is an intrinsic part of the concerted mechanism by which AMPK stimulates heart glycolysis ( Figure 7 ). PFK-2 activation by AMPK is restricted to tissues containing the heart isozyme of PFK-2. Heart and renal medulla express the heart isozyme, but this is not the case for liver or skeletal muscle. The liver and muscle PFK-2 isozymes do not contain the carboxy-terminal AMPK phosphorylation site. Therefore, in anoxic livers, no increase in fructose 2,6-bisphosphate and PFK-2 would be expected, and in fact a fall in fructose 2,6-bisphosphate content has been observed [30] . A similar observation was reported in hepatocytes incubated with AICA riboside [31] and in skeletal muscle submitted to anaerobic contraction [32] . The difference in regulation between skeletal and cardiac muscle is intriguing and the reasons for this discrepancy are not known. However, one would expect PFK-2 activation by anoxia to hold true for cancer cells that contain the inducible PFK-2 [21] or for the placental PFK-2 isozyme [22] . Our results indicate that these isozymes contain a carboxy-terminal sequence that can be phosphorylated by AMPK, possibly to a lesser extent than heart PFK-2, on the basis of peptide phosphorylation. Activation of inducible PFK-2 by AMPK together with induction of this PFK-2 isozyme could contribute to maintain the high glycolytic rate that is a characteristic feature of many tumours (Warburg effect) [21] . In conclusion, the activation of heart PFK-2 by AMPK and possibly of other PFK-2 homologues offers a new interpretation for the hypoxia-induced stimulation of glycolysis.
Materials and methods

Materials
Mutant (S466E) and wild-type recombinant heart PFK-2/FBPase-2 (His 6 -PFK-2, previously called BH1(His) 6 [17] ), total AMPK [33] and α1βγ and α2βγ AMPK isoforms [19] were purified as described. The constructs encoding wild-type and mutant His 6 -PFK-2 [17] , and α1, α2, β1 and γ1 AMPK subunits [34] have been described. A rabbit polyclonal antibody (anti-phospho-S466 antibody) was raised against the phosphorylated peptide RRN(S p )FTP (corresponding to residues 463-469 of heart PFK-2 in which Ser466 was phosphorylated). Peptides called MR6 ( 459 PVRMRRNSFT 468 of heart PFK-2), MR47 ( 455 PLMRRNSVT 463 of inducible PFK-2 [21] ) and SAMS, a synthetic peptide derived from ACC [20] , were synthesised by V. Stroobant (Ludwig Institute for Cancer Research, Brussels, Belgium).
In vitro studies
Methods for measurement of phosphorylation and dephosphorylation of His 6 -PFK-2 by purified AMPK and PP2A, respectively, the changes in kinetic properties induced by phosphorylation, and the identification of phosphorylation sites have been described [16, 17] .
In vivo studies
Hearts from fed male Wistar rats were perfused (Langendorff method) as described [24] . Perfusion conditions are detailed in the legends to the figures and tables. At the indicated times, hearts were freezeclamped and stored at -80°C. The frozen hearts were homogenised (Ultra-Turrax) at 0-4°C in 5 volume (v/w) of buffers used for the assay. For AMPK measurements, the buffer contained 50 mM Hepes at pH 7.6, 50 mM KCl, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 5 mM β-glycerophosphate, 100 nM microcystin and protease inhibitors (4 µg/ml leupeptin, 1 mM benzamidine hydrochloride, 1 µg/ml aprotinin, 0.7 µg/ml pepstatin, 0.2 mM phenylmethanesulfonyl fluoride and 4 µg/ml trypsin inhibitor). For PFK-2 assays, the buffer contained 20 mM Hepes at pH 7.5, 30 mM KCl, 20 mM NaF, 5 mM EGTA, 5 mM EDTA, 1 mM dithiothreitol, 100 nM microcystin, 0.1 mM fructose 6-phosphate, 0.3 mM glucose 6-phosphate and the protease inhibitors indicated above. High-speed supernatants (20,000 × g, 30 min) were taken for the assays. For measurements of the AMP:ATP ratio and fructose 2,6-bisphosphate, the hearts were homogenised in perchloric acid [31] or alkali [35] , respectively.
Cell culture studies
The transfection protocols were a modified calcium phosphate procedure [17] for HEK-293 cells and the lipofectamine method (following instructions provided by the manufacturer GIBCOBRL) for FTO-2B cells. When confluent, the cells were deprived of serum for 16 h and then incubated as described in the legends to the figures and tables. At the end of the incubation period, the medium was rapidly removed and the cells were immediately lysed in 0.8 ml ice-cold lysis buffer (50 mM Hepes at pH 7.5, 0.2% Triton X-100, 50 mM KF, 1 mM potassium phosphate, 5 mM EDTA, 5 mM EGTA, 1 µM microcystin, 1 mM Na 3 VO 4 , 15 mM β-mercaptoethanol, 1 mM PMSF, 1 mM benzamidine hydrochloride and 1 µg/ml leupeptin), scraped, frozen in liquid nitrogen and stored at -80°C. Phosphorylation and identification of the phosphorylated residue of transfected PFK-2 was realised as described [17] . In experiments using the dominant-negative AMPK (α1DN AMPK), transfection of wild-type α1, which is not active if expressed in the absence of the β and γ subunits [19] , was used as a control. This control gave results similar to those obtained following transfection with PFK-2 without cotransfected wild-type α1 AMPK (data not shown).
Enzyme and metabolite measurements
Total AMPK activity was assayed after precipitation with 10% (w/v) polyethylene glycol 6000, whereas the activity of the α1βγ or α2βγ isoforms of endogenous AMPK was assayed after immunoprecipitation with anti-α1 or anti-α2 antibodies [19] . All αAMPK constructs incorporated sequences encoding the Myc tag. The activity of these transfected AMPKs was assayed after immunoprecipitation with anti-Myc antibodies (Boerhinger). In all cases, conditions were set up to obtain maximal immunoprecipitation, and the activity was linear as a function of time and of protein concentration. AMPK activity was measured by phosphorylation of the synthetic peptide SAMS in the presence of 0.2 mM AMP [4] . PFK-2 was measured in a 20% (w/v) polyethylene glycol 6000 precipitate (perfused hearts) or in crude extract (cultured cells). Unless otherwise stated, PFK-2 activity [36] was measured at pH 7.1 with 1 mM fructose 6-phosphate, 3 mM glucose 6-phosphate and 5 mM MgATP. Fructose 2,6-bisphosphate was measured as described [35] and purine nucleotides were measured after their separation by HPLC [31] .
Other methods
Proteins were measured by Coomassie Blue staining or by the ninhydrin reaction after total alkaline hydrolysis, with bovine serum albumin as a standard. Kinetic constants were calculated by computer fitting of the data to a hyperbola describing the Michaelis-Menten equation by non-linear least-square regression. One unit of enzyme activity corresponds to the formation of 1 µmol (PFK-2) or 1 nmol (protein kinases and PP2A) of product per minute under the assay conditions.
Supplementary material
Supplementary material including a figure showing the correlation between AMPK activity and AMP:ATP ratio in perfused rat hearts submitted to anaerobic conditions, and four tables presenting changes in
Figure 7
Mechanism of stimulation of heart glycolysis by AMPK under anaerobic conditions. Green arrow, activation by covalent modification; dashed green arrow, allosteric stimulation; pPFK-2, phosphorylated form of heart PFK-2. The question mark indicates an indirect and still unknown mechanism. 
